Skip to main content
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
// //

Bristol-Myers Squibb Company NYSE: BMY-N

Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time

Today's Trading

Day Low 60.36
Day High 61.42
Open:60.51
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products. It offers products which includes hematology, oncology, cardiovascular and immunology. Bristol-Myers Squibb Company, formerly known as Bristol-Myers Company, is based in New York.

Fundamentals

Market Capitalization, $K
Shares Outstanding, K
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Moderate Buy

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma whose Tumors Express PD-L1 with CPS greater-than or equal to 5
- Business Wire - Fri Sep 17, 5:59AM CDT
Business Wire - CMTX
Fri Sep 17, 5:59AM CDT
Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) greater-than or equal to 5. The European Commission (EC), which has the authority to approve medicines for the European Union (EU), will now review the CHMP recommendation.
Lymphoproliferative Disorder Treatment Market Emerging Trends, Market Research, And Comprehensive Insights 2028
- AmericaNewsHour - Thu Sep 16, 9:56AM CDT
AmericaNewsHour - CMTX
Thu Sep 16, 9:56AM CDT
Research Nester released a report titled "" which delivers detailed overview of the global lymphoproliferative disorder treatment market in terms of market segmentation by route of administration, drug class, application, distribution channel and by region.
Neuroblastoma Drugs Market By Delivery, Type, Systems, End-User 2028
- AmericaNewsHour - Thu Sep 16, 8:33AM CDT
AmericaNewsHour - CMTX
Thu Sep 16, 8:33AM CDT
Research Nester published a report titled "- Global Demand Analysis and Opportunity Outlook 2020-2028" which delivers detailed overview of the neuroblastoma drugs market in terms of market segmentation by drug type, by mechanism type, by treatment type, by diagnosis type, by end users and by region.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 60.36 +1.57% increase
on 09/17/21
Period Open:68.96
Price movement based on the high, low and last over the given period.
69.75 -12.10% decrease
on 08/23/21
-7.65 (-11.09%) decrease
since 08/17/21
3-Month 60.36 +1.57% increase
on 09/17/21
Period Open:66.77
Price movement based on the high, low and last over the given period.
69.75 -12.10% decrease
on 08/23/21
-5.46 (-8.18%) decrease
since 06/17/21
52-Week 56.75 +8.03% increase
on 10/29/20
Period Open:59.40
Price movement based on the high, low and last over the given period.
69.75 -12.10% decrease
on 08/23/21
+1.91 (+3.22%) increase
since 09/17/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies